Trinity Biotech posts sharp rise in revenues

Nasdaq-quoted Trinity Biotech posted sharply higher revenues and profits for the first quarter.

Nasdaq-quoted Trinity Biotech posted sharply higher revenues and profits for the first quarter.

The Irish research company said revenues were up 38 per cent from a year earlier to $11.4 million, with pretax profit before exceptionals rising to 1.5 million from 1.1 million.

Research and development spending rose to $1.0 million in the quarter from 700,000 a year earlier.

Chief financial officer Mr Maurice Hickey said: revenues grew strongly in the first quarter, with gross margins earned of 49 per cent.

"As the benefits of the direct sales operations materialise, the objective is to increase gross margins to in excess of 50," he said.

Spending on new direct sales teams will provide the platform for future organic growth, and the company is "in a strong financial position", with bank debt of $7.6 million and cash balances of 6.2 million.

Trinity Biotech develops, manufactures and markets over 200 diagnostic products for the point-of-care, self-testing and clinical laboratory segments of the diagnostic market.

AFP

  • Join The Irish Times on WhatsApp and stay up to date

  • Sign up for push alerts to get the best breaking news, analysis and comment delivered directly to your phone

  • Listen to In The News podcast daily for a deep dive on the stories that matter